Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study

Clinical Trial

. 2008 Sep;69(9):1437-48.

doi: 10.4088/jcp.v69n0911. Epub 2008 Sep 9.

Affiliations

PMID: 19012813
DOI: 10.4088/jcp.v69n0911

Clinical Trial

Thomas J Spencer et al. J Clin Psychiatry. 2008 Sep.

Abstract

Introduction: The efficacy and safety of triple-bead mixed amphetamine salts (MAS), an oral, once-daily, enhanced extended-release amphetamine formulation designed for a duration of action up to 16 hours, were evaluated in adults with attention-deficit/hyperactivity disorder (ADHD).

Method: In this phase 3, 7-week, randomized, double-blind, multicenter, placebo-controlled, parallel-group, dose-optimization study of 272 adults with ADHD (DSM-IV-TR criteria), subjects (aged 18 to 55 years) were randomly assigned to triple-bead MAS (starting dose 12.5 mg) or placebo. The primary outcome measure was change in ADHD Rating Scale-IV (ADHD-RS-IV). Secondary outcome measures included Clinical Global Impressions (CGI) scale, Time-Sensitive ADHD Symptom Scale (TASS) (measuring extended duration), Brown Attention-Deficit Disorder Scale (BADDS) (measuring executive function), Adult ADHD Impact Module (AIM-A) (measuring quality of life [QOL]), and ADHD-RS-IV hyperactivity-impulsivity and inattentiveness subscales. Adverse events (AEs), vital signs, electrocardiograms (ECGs), and laboratory data were collected. The trial was conducted from January 2005 to June 2005.

Results: Triple-bead MAS resulted in significantly greater improvement versus placebo in mean ADHD-RS-IV total score change (p < .0001), CGI-Improvement (p < .0001), TASS total score at 13-16 hours postdose (p = .002), BADDS total score (p < .0001), all AIM-A domains (p < or = .01), and ADHD-RS-IV subscales (p < .01), demonstrating extended duration of efficacy and improvements in executive function and QOL. The most common treatment-emergent AEs included insomnia, dry mouth, decreased appetite and weight, and headache. Most treatment-emergent AEs were mild or moderate in severity.

Conclusions: Triple-bead MAS was significantly more effective than placebo in treating adult ADHD. The extended duration of action up to 16 hours and significant improvements in executive function and QOL address unique treatment needs of adults with ADHD. Treatment-emergent AEs with triple-bead MAS were consistent with amphetamine treatment.

Trial registration: ClinicalTrials.gov NCT00150579.

PubMed Disclaimer

Cited by

Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Elliott J, Johnston A, Husereau D, Kelly SE, Eagles C, Charach A, Hsieh SC, Bai Z, Hossain A, Skidmore B, Tsakonas E, Chojecki D, Mamdani M, Wells GA. Elliott J, et al. PLoS One. 2020 Oct 21;15(10):e0240584. doi: 10.1371/journal.pone.0240584. eCollection 2020. PLoS One. 2020. PMID: 33085721 Free PMC article.
Once-daily medications for the pharmacological management of ADHD in adults.
Tcheremissine OV, Lieving LM. Tcheremissine OV, et al. Ther Clin Risk Manag. 2009 Apr;5(2):367-79. doi: 10.2147/tcrm.s4206. Epub 2009 May 20. Ther Clin Risk Manag. 2009. PMID: 19536322 Free PMC article.
Post-Hoc Analyses of the Effects of Baseline Sleep Quality on SHP465 Mixed Amphetamine Salts Extended-Release Treatment Response in Adults with Attention-Deficit/Hyperactivity Disorder.
Surman CBH, Robertson B, Chen J, Cortese S. Surman CBH, et al. CNS Drugs. 2019 Jul;33(7):695-706. doi: 10.1007/s40263-019-00645-z. CNS Drugs. 2019. PMID: 31228031 Free PMC article. Clinical Trial.
Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women.
Epperson CN, Pittman B, Czarkowski KA, Bradley J, Quinlan DM, Brown TE. Epperson CN, et al. Menopause. 2011 May;18(5):542-8. doi: 10.1097/gme.0b013e3181fcafd6. Menopause. 2011. PMID: 21293309 Free PMC article. Clinical Trial.
Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants.
Weyandt LL, Oster DR, Marraccini ME, Gudmundsdottir BG, Munro BA, Zavras BM, Kuhar B. Weyandt LL, et al. Psychol Res Behav Manag. 2014 Sep 9;7:223-49. doi: 10.2147/PRBM.S47013. eCollection 2014. Psychol Res Behav Manag. 2014. PMID: 25228824 Free PMC article. Review.

Triple-bead mixed amphetamine salts (SPD465), a novel, enhanced extended-release amphetamine formulation for the treatment of adults with ADHD: a randomized, double-blind, multicenter, placebo-controlled study - PubMed (original) (raw)